Most cancer cells shift their metabolic pathway from a metabolism reflecting the Pasteur-effect into one reflecting the Warburg-effect. This shift creates an acidic microenvironment around the tumor and becomes the driving force for a positive carcinogenesis feedback loop. As a consequence of tumor acidity, the tumor microenvironment encourages a selection of certain cell phenotypes that are able to survive in this caustic environment to the detriment of other cell types. This selection can be described by a process which can be modeled upon spite: the tumor cells reduce their own fitness by making an acidic environment, but this reduces the fitness of their competitors to an even greater extent. Moreover, the environment is an important dimension that further drives this spite process. Thus, diminishing the selective environment most probably interferes with the spite process. Such interference has been recently utilized in cancer treatment.
References
[1]
Racker, E. History of the Pasteur effect and its pathobiology. Mol. Cell Biochem.？1974, 5, 17–23, doi:10.1007/BF01874168. 4279327
[2]
Gatenby, R.A.; Gillies, R.J. Why cancers have high aerobic glycolysis? Nat. Rev. Cancer？2004, 4, 891–899, doi:10.1038/nrc1478. 15516961
Fais, S.; De Milito, A.; You, H.; Qin, W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res.？2007, 67, 10627–10630, doi:10.1158/0008-5472.CAN-07-1805. 18006801
[8]
Silva, A.S.; Yunes, J.A.; Gillies, R.J.; Gatenby, R.A. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res.？2009, 15, 2677–2684.
Fais, S. Cannibalism: a way to feed on metastatic tumors. Cancer Lett.？2007, 258, 155–164, doi:10.1016/j.canlet.2007.09.014. 17977647
[11]
Lugini, L.; Lozupone, F.; Matarrese, P.; Funaro, C.; Luciani, F.; Malorni, W.; Rivoltini, L.; Castelli, C.; Tinari, A.; Piris, A.; Parmiani, G.; Fais, S. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: A key role of ezrin. Lab Invest.？2003, 83, 1555–1567, doi:10.1097/01.LAB.0000098425.03006.42. 14615410
[12]
Lugini, L.; Matarrese, P.; Tinari, A.; Lozupone, F.; Federici, C.; Iessi, E.; Gentile, M.; Luciani, F.; Parmiani, G.; Rivoltini, L.; Malorni, W.; Fais, S. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res.？2006, 66, 3629–2638, doi:10.1158/0008-5472.CAN-05-3204. 16585188
[13]
Lozupone, F.; Perdicchio, M.; Brambilla, D.; Borghi, M.; Meschini, S.; Barca, S.; Marino, M.L.; Logozzi, M.; Federici, C.; Iessi, E.; De Milito, A.; Fais, S. The human homologue of Dictyostelium discoideum phg1A is expressed by human metastatic melanoma cells. EMBO Rep.？2009, 10, 1348–1354, doi:10.1038/embor.2009.236. 19893578
[14]
Goss, P.E.; Chamebrs, A.F. Does tumour dormancy offer a therapeutic target? Nat. Rev. Cancer？2010, 10, 871–877, doi:10.1038/nrc2933. 21048784
[15]
Gatenby, R.A.; Gillies, R.J. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer？2008, 8, 56–61, doi:10.1038/nrc2255. 18059462
[16]
Huber, V.; De Milito, A.; Harguindey, S.; Reshkin, S.J.; Wahl, M.L.; Rauch, C.; Chiesi, A.; Pouysségur, J.; Gatenby, R.A.; Rivoltini, L.; Fais, S. Proton dynamics in cancer. J. Transl. Med.？2010, 8, 57, doi:10.1186/1479-5876-8-57. 20550689
[17]
Fais, S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J. Intern. Med.？2010, 267, 515–525, doi:10.1111/j.1365-2796.2010.02225.x. 20433578
[18]
Luciani, F.; Spada, M; De Milito, A.; Molinari, A.; Rivoltini, L.; Montinaro, A.; Marra, M.; Lugini, L.; Logozzi, M.; Lozupone, F.; Federici, C.; Iessi, E.; Parmiani, G.; Arancia, G.; Belardelli, F.; Fais, S. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl. Cancer Inst.？2004, 96, 1702–1713, doi:10.1093/jnci/djh305. 15547183
[19]
Abbate, F.; Casini, A.; Owa, T.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett.？2004, 14, 217–223, doi:10.1016/j.bmcl.2003.09.062. 14684331
[20]
Genis, C.; Sippel, K.H.; Case, N.; Cao, W.; Avvaru, B.S.; Tartaglia, L.J.; Govindasamy, L.; Tu, C.; Agbandje-McKenna, M.; Silverman, D.N.; Rosser, C.J.; McKenna, R. Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties. Biochemistry？2009, 48, 1322–1331, doi:10.1021/bi802035f. 19170619
[21]
Teicher, B.A.; Liu, S.D.; Liu, J.T.; Holden, S.A.; Herman, T.S. A. carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res.？1993, 13, 1549–1556. 8239534
Harguindey, S.; Orive, G.; Pedraz, J.L.; Paradiso, A.; Reshkin, S.J. The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin-one single nature. Biochim. Biophys. Acta？2005, 1756, 1–24. 16099110
[24]
Orive, G.; Reshkin, S.J.; Harguindey, S.; Pedraz, J.L. Hydrogen ion dynamics and the Na+/H+ exchanger in cancer angiogenesis and antiangiogenesis. Br. J. Cancer？2003, 89, 1395–1399, doi:10.1038/sj.bjc.6601286. 14562004
[25]
Arakaki, N.; Nagao, T.; Niki, R.; Toyofuku, A.; Tanaka, H.; Kuramoto, Y.; Emoto, Y.; Shibata, H.; Magota, K.; Higuti, T. Possible role of cell surface H+ -ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. Mol. Cancer Res.？2003, 1, 931–939. 14638865
[26]
Kelkel, M.; Jacob, C.; Dicato, M.; Diederich, M. Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies. Molecules？2010, 15, 7035–7074, doi:10.3390/molecules15107035. 20944521
[27]
Patel, V.B.; Misra, S.; Patel, B.B.; Majumdar, A.P. Colorectal cancer: Chemopreventive role of curcumin and resveratrol. Nutr. Cancer？2010, 62, 958–967, doi:10.1080/01635581.2010.510259. 20924971
[28]
De Milito, A.; Fais, S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol.？2005, 1, 779–786, doi:10.2217/14796694.1.6.779. 16556057
[29]
De Milito, A.; Fais, S. Proton pump inhibitors may reduce tumour resistance. Expert Opin. Pharmacother.？2005, 6, 1049–1054, doi:10.1517/14656566.6.7.1049. 15957961
[30]
Axelrod, R.; Axelrod, D.E.; Pienta, K.J. Evolution of cooperation among tumor cells. Proc. Natl. Acad. Sci. USA？2006, 103, 13474–13479, doi:10.1073/pnas.0606053103. 16938860
[31]
Certo, M.; Moore, D.V.; Nishino, M.; Wei, G.; Korsmeyer, S.J.; Armstrong, SA; Letai, A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell？2006, 9, 351–365, doi:10.1016/j.ccr.2006.03.027. 16697956
[32]
Martin, N.K.; Gaffney, E.A.; Gatenby, R.A.; Maini, P.K. Tumour-stromal interactions in acid-mediated invasion: a mathematical model. J. Theor. Biol.？2010, 267, 461–470, doi:10.1016/j.jtbi.2010.08.028. 20816684
